Vor Bio back from brink with autoimmune drug deal rising to $4bn
A month and a half after winding operations and laying off almost all its staff, Vor Bio has emerged from…
Immunology
-
-
US FDA approves GSK’s Benlysta autoinjector for lupus nephritis
The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five years…
-
Harbour BioMed partners Otsuka on new T-cell therapy
Harbour BioMed has entered a strategic partnership with Otsuka Pharmaceutical focusing on the development of HBM7020, a B-cell maturation antigen…
-
DoH – Abu Dhabi and Sanofi link for vaccine development
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine…
-
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP)…
-
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster…
-
Vertex halts development of diabetes cell therapy after trial failure
Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device,…
-
Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
Sanofi is continuing its immunology pipeline push with an agreement to acquire Dren Bio’s bispecific antibody DR-0201 in a deal…
-
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune…
-
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company…
